Regeneron Pharmaceuticals Inc. buy PapaSmurf
Start price
19.10.19
/
50%
€268.00
Target price
19.12.19
-
Performance (%)
25.13%
End price
19.12.19
€335.35
Summary
This prediction ended on 19.12.19 with a price of €335.35. The BUY prediction by PapaSmurf finished with a performance of 25.13%. PapaSmurf has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.890% | 0.890% | 18.994% | -25.628% |
| iShares Core DAX® | 1,75 % | 2,66 % | 6,83 % | 50,94 % |
| iShares Nasdaq 100 | 4,30 % | 6,59 % | 40,47 % | 94,14 % |
| iShares Nikkei 225® | 9,89 % | 18,28 % | 67,99 % | 77,79 % |
| iShares S&P 500 | 2,54 % | 3,06 % | 26,76 % | 67,59 % |
Comments by PapaSmurf for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Buy Regeneron Pharmaceuticals Inc.